Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns

Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns

Introduction: Adverse events associated with vaccine administration can manifest in the oral cavity and orofacial region. Hence, the aim of this study was to compare the orofacial adverse effects of two recently authorised COVID-19 vaccines, namely BNT162b2 and mRNA-1273. Methods: Publicly available...

Full description

Bibliographic Details
Main Author:	Cirillo, N. (Author)
Format:	Article
Language:	English
Published:	Blackwell Publishing Ltd 2021
Subjects:	adverse drug reaction anaphylaxis Article Bell palsy Bell's palsy bnt 162b 2 BNT162 vaccine BNT162b2 Canada chadox1 ncov 19 comparative study consumer coronavirus disease 2019 COVID-19 COVID-19 Vaccines Europe European Union face edema facial droop health care personnel human Humans infection prevention lip swelling maxillofacial disorder mRNA-1273 mRNA-1273 vaccine multicenter study priority journal SARS-CoV-2 side effects tongue edema tozinameran United Kingdom United States vaccination Vaccine
Online Access:	View Fulltext in Publisher

Similar Items

Facial and Oral Manifestations Following COVID-19 Vaccination: A Survey-Based Study and a First Perspective
by: Marta Mazur, et al.
Published: (2021-05-01)

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
by: Chiranjib Chakraborty, et al.
Published: (2021-07-01)

Proteome Organization of COVID-19: Illustrating Targets for Vaccine Development
by: Alok Bharadwaj, et al.
Published: (2020-05-01)

Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers
by: Louise Benning, et al.
Published: (2021-08-01)

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
by: Ahmed Zaqout, et al.
Published: (2021-07-01)

Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals
by: Yosuke Hirotsu, et al.
Published: (2021-08-01)

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
by: Emanuel Zitt, et al.
Published: (2021-06-01)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
by: Takeshi Terashima
Published: (2021-01-01)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
by: Andrea Lombardi, et al.
Published: (2021-08-01)

A novel adverse effect of the BNT162b2 mRNA vaccine: First episode of acute mania with psychotic features
by: Umit Haluk Yesilkaya, et al.
Published: (2021-12-01)

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
by: Alexandre Vallée, et al.
Published: (2021-08-01)

Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection
by: Ilaria Vicenti, et al.
Published: (2021-07-01)

Effectiveness of BNT162b2 COVID-19 Vaccine in Preventing Severe Symptomatic Infection among Healthcare Workers
by: Efrén Murillo-Zamora, et al.
Published: (2021-07-01)

May polyethylene glycol be the cause of anaphylaxis to mRNA COVID-19 vaccines?
by: Pedro Giavina-Bianchi, et al.
Published: (2021-04-01)

A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population
by: Chinonyerem O. Iheanacho, et al.
Published: (2021-08-01)

BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees
by: Ahmed N. Alghamdi, et al.
Published: (2021-10-01)

Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection
by: Anna Patrignani, MD, et al.
Published: (2021-11-01)

Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany
by: Manuela A. Hoffmann, et al.
Published: (2021-08-01)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
by: Hiroaki Akiyama, et al.
Published: (2021-01-01)

Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers
by: Yu-Mi Wi, et al.
Published: (2021-08-01)

Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
by: Ilaria Vicenti, et al.
Published: (2021-11-01)

Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies
by: Donato Amodio, et al.
Published: (2021-10-01)

Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection
by: José Javier Morales-Núñez, et al.
Published: (2021-07-01)

Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response
by: Yoav Rechavi, et al.
Published: (2021-09-01)

Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine
by: Annalisa Ciabattini, et al.
Published: (2021-09-01)

Antibodies against Receptor Binding Domain of SARS-CoV-2 spike protein induced by BNT162b2 vaccine: results from a pragmatic, real-life study
by: Marcello Mariani, et al.
Published: (2021-10-01)

Outbreak of infections with the COVID-19 virus mutation B.1.351 about four weeks after the second successful vaccination with BNT162b2
by: Ortloff, Andrea, et al.
Published: (2021-04-01)

Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2
by: Marcello Salvaggio, et al.
Published: (2021-09-01)

Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals
by: Daniel Lozano-Ojalvo, et al.
Published: (2021-08-01)

Polymyalgia rheumatica as uncommon adverse event following immunization with COVID‐19 vaccine: A case report and review of literature
by: Ciro Manzo, et al.
Published: (2021-09-01)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
by: Giovanna Cocomazzi, et al.
Published: (2021-08-01)

Acute myocarditis following administration of BNT162b2 vaccine
by: Mhd Baraa Habib, et al.
Published: (2021-01-01)

Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers
by: Niki Vassilaki, et al.
Published: (2021-08-01)

SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination
by: Cipolletta, D., et al.
Published: (2022)

Vaccin mot SARS-CoV-2 – en utvärdering av effektivitet och säkerhet av ledande vaccin : En Litteraturstudie
by: Wrywood, Sean
Published: (2021)

Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
by: Mina Psichogiou, et al.
Published: (2021-09-01)

Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers
by: Antonella d'Arminio Monforte, et al.
Published: (2021-06-01)

Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study
by: Alcamí, J., et al.
Published: (2022)

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
by: Nick K Jones, et al.
Published: (2021-04-01)

Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination
by: Brent Appelman, et al.
Published: (2021-10-01)